Tele-Prescribing in the Crosshairs: Navigating the Latest Regulatory Activity Coming From the DEA, HHS, and Other Agencies Governing Tele-Prescriptions of Controlled Substances

Libby Baney
Partner
Fargre Drinker Biddle & Reath LLP

Thomas Ferrante
Partner
Foley & Lardner LLP

Hilda Gurley
Principal
Pharmacy Compliance Strategies, LLC

Kaytie M. Ravega
Partner
Quarles & Brady LLP
- Examining the evolution of the Ryan Haight Act since 2008
- Tackling the uncertainty of looming rule changes by the DEA & SAMHSA to the prescription of controlled substances via telemedicine
- Addressing how telehealth providers can operationalize new regulatory changes coming down the pike without sacrificing efficiency, business growth and their bottom line
- Critical takeaways for efficient and compliant Telepharmacy implementation efforts
- Taking a look at concrete real-life scenarios where tele-prescribing practices have come under agency scrutiny
- What telehealth companies need to know about the FDA’s new proposed rule on Nonprescription Drug Products with an Additional Condition for Nonprescription Use